HAVCR2 (TIM-3): A novel mechanism of immune checkpoint regulation and its potential in tumor therapy

introduction

   
In March 2016, Nature Reviews Clinical Oncology published a review titled "PD-1 says goodbye, TIM-3 says hello", pushing HAVCR2 (encoding TIM-3 protein) to the forefront of tumor immunotherapy research. As an important member of the TIM family (TIM1/HAVCR1, TIM3/HAVCR2, TIM4/TIMD4), TIM-3 has attracted much attention for its critical role in autoimmune and tumor immune regulation.

  
Biological characteristics of TIM-3
    
  
TIM-3 (T cell immunoglobulin and mucin domain containing protein 3) was initially identified as a marker receptor for IFN - γ+CD4+/CD8+T cells, and subsequent studies have confirmed its expression in regulatory T cells (Treg), dendritic cells (DCs), NK cells, and myeloid cells. Its structural features include:
N-terminal IgV domain: mediating ligand recognition

Mucin like domain: involved in signal transduction

Transmembrane region and cytoplasmic tail: transmitting inhibitory signals

  
  
Ligand interaction network and functional regulation

  
TIM-3 achieves immune microenvironment specific regulation through a multi ligand system (Figure 1):

  
1. Galectin-9
Mechanism of action: Binding to glycosylation sites in the TIM-3 IgV domain induces calcium influx and T cell apoptosis
Pathological significance: Mediating T cell depletion in tumor microenvironment (TME)

  
2. Phosphatidylserine (PtdSer)
Functional features:
Promote antigen cross presentation of TIM-3+DCs
Regulating the clearance of apoptotic cells through the "eat me" signaling pathway

  
3. HMGB1
Research progress: Although identified as a TIM-3 ligand, its binding site and downstream pathways are still unclear

4. CEACAM1
Regulatory complexity:
Display of anticancer effect in colorectal cancer model (CEACAM1 −/− increased tumor burden in mice)

High expression in melanoma can inhibit T cell function
Therapeutic targeting: The efficacy of anti-TIM-3 antibodies is positively correlated with interference with TIM-3/CEACAM1 binding ability

the core role of TIM-3 in tumor immune escape  

1. T cell regulation

  
Exhaustion markers: TIM-3+PD-1+CD8+T cells are the most significantly dysfunctional subset
Clinical association: High expression of TIM-3 is significantly associated with poor prognosis in patients with NSCLC, CRC, etc. (HR=1.8-2.3, p<0.01)

2. Non T cell function

  
Progress in Clinical Translational Research

  
1. Limitations of monotherapy
TSR-022 (Tesaro): Only one sarcoma patient achieved PR in phase I trial, ORR<5%
Mechanism bottleneck: TIM-3 blockade relies on synergistic activation of the PD-1 pathway

  
2. Combination therapy strategy
PD-1 inhibitor: significantly increases ORR in melanoma/CRC model (mouse model: monotherapy 20% vs combination 60%)
New combination:
LY3321367 (Lilly)+PD-1 antibody: Phase I shows controllable toxicity (Gr3-4 AE<15%)
Bispecific antibody RO7121661: synchronously targeting TIM-3/PD-1, has entered phase I clinical trials
   
   
Challenges and Prospects

  
1,Molecular Mechanism Deepening: Need to Analyze the Heterogeneity of TIM-3 Signal Transduction in Different Immune Cells
2,Biomarker development: patient stratification strategy based on TIM-3 expression profile
3,Next generation drug design:
Allosteric regulatory antibodies (selectively blocking specific ligands)
Three specific antibodies (TIM-3/PD-1/LAG-3)

Conclusion: HAVCR2, as an emerging target for immunotherapy, provides a new approach for overcoming PD-1 resistance due to its multicellular regulatory properties. With a deeper understanding of TIM-3 ligand interactions and tissue-specific functions, precise intervention strategies targeting this pathway are expected to become an important breakthrough point in tumor immunotherapy.